Zobrazeno 1 - 10
of 119
pro vyhledávání: '"PETER FENICI"'
Autor:
Jordi Real, Bogdan Vlacho, Emilio Ortega, Joan Antoni Vallés, Manel Mata-Cases, Esmeralda Castelblanco, Eric T. Wittbrodt, Peter Fenici, Mikhail Kosiborod, Dídac Mauricio, Josep Franch-Nadal
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Background Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared
Externí odkaz:
https://doaj.org/article/a7e7ad8919684a4ebb9ce7e799f82d86
Autor:
Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi, Avraham Karasik, Dianna J. Magliano, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, the CVD-REAL Investigators and Study Group
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Abstract Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-
Externí odkaz:
https://doaj.org/article/84b501fd6bee4a8d9bef97cb73d7d10c
Autor:
Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Larisa Ramirez, Marina V. Shestakova, Iichiro Shimomura, Filip Surmont, Fengming Tang, Jiten Vora, Hirotaka Watada, Mikhail Kosiborod, the DISCOVER investigators
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1711-1716 (2021)
Abstract Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of HF in T2D are not well defined. This study aimed to examine t
Externí odkaz:
https://doaj.org/article/6f0d5cf6e07a4fcc98c4a0e71fee4e3d
Autor:
Marília B. Gomes, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Kamlesh Khunti, Wolfgang Rathmann, Marina V. Shestakova, Filip Surmont, Hirotaka Watada, Jesús Medina, Iichiro Shimomura, Gabriela Luporini Saraiva, Andrew Cooper, Antonio Nicolucci
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
DISCOVER is a 3-year observational study program of 15,983 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. We investigated the association between socioeconomic status and both the availability of a baseli
Externí odkaz:
https://doaj.org/article/6c2277abaa80486181f4c6426ca2717c
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-19 (2020)
Abstract Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage kidney disease (ESKD) requiring d
Externí odkaz:
https://doaj.org/article/8374db7c3dac42abafac7e6378df85a3
Autor:
Suzanne V. Arnold, Kamlesh Khunti, Fengming Tang, Hungta Chen, Antonio Nicolucci, Marilia B. Gomes, Linong Ji, Marina V. Shestakova, Hirotaka Watada, Andrew Cooper, Peter Fenici, Niklas Hammar, Jesús Medina, Mikhail Kosiborod, the DISCOVER investigators
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background The key goals of management in patients with type 2 diabetes (T2D) are to prolong life and improve quality of life. Micro‐ and macrovascular complications of T2D not only increase the risk of morbidity and mortality, but cross
Externí odkaz:
https://doaj.org/article/9ed190f5132449e2ae21f646b8e71319
Autor:
Jesús Medina, Peter Fenici, Linong Ji, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Wolfgang Rathmann, Suzanne V Arnold, Iichiro Shimomura, Mikhail Kosiborod, Hungta Chen, Andrew Cooper, Brenda Bongaerts, Bernard H Charbonnel, Marilia Gomes, Marina Shestakova
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction Although individualized target glycated hemoglobin (HbA1c) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged
Externí odkaz:
https://doaj.org/article/43da6cdaaf924397ad77881be216d19f
Autor:
Peter Fenici, Niklas Hammar, Linong Ji, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Wolfgang Rathmann, Iichiro Shimomura, Marilia B Gomes, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Hungta Chen, Javier Cid-Ruzafa
Publikováno v:
BMJ Open, Vol 10, Iss 8 (2020)
Objectives To evaluate the extent to which patients with type 2 diabetes discontinue metformin therapy when initiating second-line treatment and factors associated with metformin discontinuation, using baseline data from the DISCOVER study programme.
Externí odkaz:
https://doaj.org/article/3fa27abaed344ef894964068e1189e22
Autor:
Mikhail Kosiborod, Marilia B. Gomes, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Marina V. Shestakova, Hirotaka Watada, Iichiro Shimomura, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Niklas Hammar, Filip Surmont, Fengming Tang, Kamlesh Khunti, for The DISCOVER investigators
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Abstract Background The global prevalence of type 2 diabetes-related complications is not well described. We assessed prevalence of vascular complications at baseline in DISCOVER (NCT02322762; NCT02226822), a global, prospective, observational study
Externí odkaz:
https://doaj.org/article/fbc8805de658404293adbd290ad8feef
Autor:
John Wilding, Thomas Godec, Kamlesh Khunti, Stuart Pocock, Robin Fox, Liam Smeeth, Per Clauson, Peter Fenici, Niklas Hammar, Jesús Medina
Publikováno v:
BMC Medicine, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background Intensification of metformin monotherapy with additional glucose-lowering drugs is often required in patients with type 2 diabetes (T2D). This study evaluated changes in HbA1c and weight, as well as treatment persistence, associat
Externí odkaz:
https://doaj.org/article/7ebfc4fe14464ddf82451f2fd37841f9